Colorectal cancer surgery: is further research necessary?

Bailey, Craig R.; George, Marc

doi:10.1111/anae.15706

Cited by 5 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Colorectal cancer is the most common malignant tumor of the digestive system, and it seriously affects patients’ quality of life 1 , 2 . Surgery is the primary treatment option for colorectal cancer, but the recurrence rate is as high as 30% 3 . Therefore, chemotherapy combined with surgery has become the current dominant strategy in the treatment of colorectal cancer 4 – 6 .…”

Section: Introductionmentioning

confidence: 99%

B-Myb deficiency boosts bortezomib-induced immunogenic cell death in colorectal cancer

Hui,

Yu,

et al. 2024

Sci Rep

View full text Add to dashboard Cite

B-Myb has received considerable attention for its critical tumorigenic function of supporting DNA repair. However, its modulatory effects on chemotherapy and immunotherapy have rarely been reported in colorectal cancer. Bortezomib (BTZ) is a novel compound with chemotherapeutic and immunotherapeutic effects, but it fails to work in colorectal cancer with high B-Myb expression. The present study was designed to investigate whether B-Myb deletion in colorectal cancer could potentiate the immune efficacy of BTZ against colorectal cancer and to clarify the underlying mechanism. Stable B-Myb knockdown was induced in colorectal cancer cells, which increased apoptosis of the cancer cells relative to the control group in vitro and in vivo. We found that BTZ exhibited more favourable efficacy in B-Myb–defective colorectal cancer cells and tumor-bearing mice. BTZ treatment led to differential expression of genes enriched in the p53 signaling pathway promoted more powerful downstream DNA damage, and arrested cell cycle in B-Myb–defective colorectal cancer. In contrast, recovery of B-Myb in B-Myb–defective colorectal cancer cells abated BTZ-related DNA damage, cell cycle arrest, and anticancer efficacy. Moreover, BTZ promoted DNA damage–associated enhancement of immunogenicity, as indicated by potentiated expression of HMGB1 and HSP90 in B-Myb–defective cells, thereby driving M1 polarization of macrophages. Collectively, B-Myb deletion in colorectal cancer facilitates the immunogenic death of cancer cells, thereby further promoting the immune efficacy of BTZ by amplifying DNA damage. The present work provides an effective molecular target for colorectal cancer immunotherapy with BTZ.

show abstract

Section: Introductionmentioning

confidence: 99%

B-Myb deficiency boosts bortezomib-induced immunogenic cell death in colorectal cancer

Hui,

Yu,

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

“…For midline surgical incisions, there are alternative modes of analgesia apart from thoracic epidural or rectus sheath catheters [5] that could have been considered and may well have resulted in an improved experience. These include single‐shot spinal anaesthesia using a combination of local anaesthetic and diamorphine [6]; erector spinae plane (ESP) or transversus abdominus plane (TAP) block; [7] lidocaine infusion [8]; or opioid‐based patient‐controlled analgesia. This particular randomised controlled trial had dynamic pain scores at 24 h after surgery as its primary outcome measure, and whilst incisional pain has previously been cited by patients as an important issue to avoid (together with nausea and vomiting and gagging on the tracheal tube) [9] it could be argued that when planning trials we should be including outcomes which are more pertinent to patients' expectations.…”

mentioning

confidence: 99%